Extracellular Matrix/Metastasis Modifier Genes as a Method for Characterization and Prevention of Metastatic Tumor
Description of Invention:
To a large extent cancer mortality is due to metastatic disease than a primary tumor. Recent evidence suggests that metastatic disease can be an early event and in majority of patients metastasis starts by the time the disease is diagnosed. Thus there is a need for methods of characterizing the early metastatic process for better treatment of cancer.
This invention provides methods of characterizing the metastatic capacity of a tumor as well as inhibiting metastasis of a cancer cell. More specifically, this invention discloses an extracellular matrix (ECM) modifier protein named Anakin, detection of the Anakin protein as a marker for metastatic disease and use of Anakin as potential therapeutic target.
Applications and Modality:
Method of diagnosis for early metastasis and therapeutic inhibition of metastasis
Nucleic acid sequence of Anakin protein, an extracellular matrix (ECM) modifier gene
SiRNA sequences that inhibit Anakin expression as therapeutics
Purified antibodies that recognize Anakin protein as a research reagent and in diagnostics related products
Market:
600,000 deaths from cancer related diseases estimated in 2006.
Development Status:
The technology is currently in the pre-clinical stage of development.
Patent Status:
DHHS Reference No. E-125-2006/1 --
U.S. Provisional Application No. 60/778,463 filed 31 Mar 2006
Licensing Status: Available for exclusive and non-exclusive licensing.
Collaborative Research Opportunity:
The NCI Laboratory of Population Genetics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Anakin as a prognostic tool for diagnosing breast cancer outcome. Please contact John Hewes, Ph.D., at 301-435-3121 for more information.
Portfolios: Cancer
Cancer -Diagnostics-In Vivo-MAb Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
